Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2067526
Abstract: ABSTRACT Introduction The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and a… read more here.
Keywords: btk inhibitor; btk; cardiotoxicity btk; inhibitors ibrutinib ... See more keywords
Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12123731
Abstract: Simple Summary The enzyme aldo-keto reductase 1C3 (AKR1C3) is present in several cancers, in which it is capable of actively metabolising different chemotherapy drugs and decreasing their cytotoxic effects. Therefore, the combination with specific inhibitors… read more here.
Keywords: ibrutinib acalabrutinib; inhibitors ibrutinib; cancer cells; cancer ... See more keywords